MAP Pharmaceuticals Sets IPO Pricing

Mountain View-based MAP Pharmaceuticals, a biopharmaceuticals firm developing treatments for pediatric asthma and migraines, has set pricing for its IPO. In a filing with the SEC, the firm said that it will offer 5 million shares of its common stock in at between $14.00 and $16.00 per share. MAP Pharmaceuticals IPO is being underwritten by Merrill Lynch & Co., Morgan Stanley, and Deutsche Bank Securities; the firm will trade on the Nasdaq Global Market under the symbol "MAPP."